Schernberg A., Sagaon Teyssier Luis, Schwarzinger M., Baillot S., Bec M., Benmahammed L., Even C., Geoffrois L., Huguet F., Le Vu B., Levy-Bachelot L., Luchini S., Pointreau Y., Robert C., Temam S., Epicorl Study Group. (2019). Clinical and economic burden of head and neck cancer : a nationwide retrospective cohort study from France. Clinicoeconomics and Outcomes Research, 11, p. 441-451. ISSN 1178-6981.
Titre du document
Clinical and economic burden of head and neck cancer : a nationwide retrospective cohort study from France
Année de publication
2019
Auteurs
Schernberg A., Sagaon Teyssier Luis, Schwarzinger M., Baillot S., Bec M., Benmahammed L., Even C., Geoffrois L., Huguet F., Le Vu B., Levy-Bachelot L., Luchini S., Pointreau Y., Robert C., Temam S., Epicorl Study Group
Source
Clinicoeconomics and Outcomes Research, 2019,
11, p. 441-451 ISSN 1178-6981
Objectives: To evaluate the clinical and economic burden of head and neck squamous cell carcinoma (HNSCC) in France. Methods: All 53,255 incident adult patients discharged with a first diagnosis of HNSCC in 2010-2012 were identified from the 2008-2013 French National Hospital Discharge (PMSI) database. We conducted a retrospective longitudinal analysis of prognosis and direct costs attributable to HNSCC. Results: Direct medical costs attributable to HNSCC care amounted to 665 million euros in 2012 in France. The majority (62%) of incident patients were 64 years old or less at HNSCC diagnosis and incurred 1.3-fold higher mean direct costs as compared to elderly patients (41,909 vs 32,221 euros over 3 years, respectively; p<0.001). HNSCC stage at initial treatment was the major driver of mean (SD) direct costs over 3 years (p<0.001): 19,819 (23,150) euros in 31% patients diagnosed at early stage; 46,791 (34,841) euros in 60% patients diagnosed at locally advanced stage; and 43,377 (33,953) euros in 9% patients diagnosed with distant metastasis. About half patients died over 3 years at a median (IQR) age of 63 (56-75) years resulting in 10.9 years-of-life lost on average per incident patient. Conclusion: The present study suggests that the clinical and economic burden of HNSCC is substantial in France.
Plan de classement
Santé : aspects socioculturels, économiques et politiques [056]
Description Géographique
FRANCE
Localisation
Fonds IRD [F B010076249]
Identifiant IRD
fdi:010076249